shu-508 and Thyroid-Neoplasms

The utility of ultrasound color Doppler flow mapping imaging for the differential diagnosis on the breast and thyroid tumors had already reported in 1991. Ultrasound contrast agent, SH/TA 508 (Levovist; Schering AG, Germany), had already finished clinical trials in Japan and reported the result phase II, III. On the breast and thyroid lesions, the utility of this contrast agent are safety and usefulness for the accurate diagnosis by the ultrasound color Doppler examination. Throughout of these clinical trials, a quit new ultrasound Doppler imaging methods had been developed, Harmonic Imaging and acoustic emission mode. As the result, ultrasound contrast agent is useful not only for the conventional color Doppler diagnosis but also for the developing of new diagnostic imaging methods.

Topics: Breast Neoplasms; Contrast Media; Female; Humans; Polysaccharides; Thyroid Neoplasms; Ultrasonography, Doppler, Color

The objective of this study was to evaluate the usefulness of a galactose-based ultrasonographic contrast agent, Levovist (Schering AG, Berlin, Germany), in differentiating benign from malignant thyroid nodules by analysis of the time-intensity curves correlating the variation of the intensity signal value during the contrast transit time. Fifty-four patients scheduled for surgical removal of a nodule or the thyroid gland or both after cytologic examination were enrolled in this study; all of the nodules underwent a baseline color and power Doppler evaluation and then to a color Doppler examination after an intravenous bolus injection of Levovist. The time-intensity curves were analyzed with respect to the histologic results. Carcinomas showed a significantly earlier arrival time of Levovist than nodular hyperplastic benign nodules and adenomas (8.1 +/- 1.41 versus 19.6 +/- 2.2 and 16.1 +/- 2.8 seconds; P < .0001), although no significant difference occurred between hyperplastic benign nodules and adenomas; carcinomas and adenomas showed an earlier time to peak than hyperplastic benign nodules (14.6 +/- 1.2 and 23.1 +/- 3.8 versus 33.0 +/- 3.0 seconds; P < .0001). No significant difference was found in baseline, peak, final intensity signal, and percent variation of intensity signal among hyperplastic benign nodules, adenomas, and carcinomas. Although cytologic examination still remains the standard of reference for the presurgical diagnosis of thyroid nodules, the preliminary data of this pilot study demonstrate that the analysis of time-intensity curves after Levovist injection might provide useful, complementary, and quantitative information to differentiate benign from malignant thyroid nodules.

Topics: Adult; Aged; Analysis of Variance; Contrast Media; Diagnosis, Differential; Female; Humans; Injections, Intravenous; Male; Middle Aged; Pilot Projects; Polysaccharides; Thyroid Neoplasms; Thyroid Nodule; Ultrasonography, Doppler, Color